Drug Discovery
LEQEMBI is now available for patients with mild cognitive impairment (MCI) or mild dementia, collectively referred to as early AD, the population in which ...
July 11, 2024 | News
DP Technology, an "AI for Science" paradigm-driven company, announced the nomination of DPT0416, a novel CNS penetrable small molecule targeting Lp-P...
July 10, 2024 | News
A*STAR’s Genome Institute of Singapore (GIS) has secured nearly SGD$18 million to develop an innovative data platform, TISHUMAP1. This platform is se...
July 09, 2024 | News
- Following its initial approval for the treatment of relapsed/refractory multiple myeloma (R/R MM), XPOVIO® has now received approval as a monoth...
July 08, 2024 | News
Genexine a publicly-listed, clinical-stage Korean biopharmaceutical company committed to the discovery and development of novel biologics for the tre...
July 05, 2024 | News
Eleva, a pioneer in unlocking difficult-to-produce biologics based on a breakthrough manufacturing platform, announced today that the European Commis...
July 04, 2024 | News
PharmAbcine, a clinical-stage public company developing next generation therapeutics to treat medical unmet needs, announced today the decision to advance ...
July 02, 2024 | News
The European Commission (EC) has authorized the marketing of OBGEMSA™ (vibegron) by Pierre Fabre Laboratories for the symptomatic treatment of overac...
July 01, 2024 | News
Global life sciences leader Cytiva is addressing the distinct filtration needs of customers manufacturing high-concentration biologic drugs with its Supor ...
June 28, 2024 | News
- XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health Insurance Service (NHIS) for the treat...
June 27, 2024 | News
Simcere Zaiming, an innovative oncology company and a subsidiary of Simcere Pharmaceutical Group (2096.HK), announced that Enlituo® (generic name: cetu...
June 27, 2024 | News
— Approval for previously treated metastatic colorectal cancer based on results from positive, global, Phase III FRESCO-2 Trial — — FRUZ...
June 24, 2024 | News
Menarini Asia-Pacific (Menarini) announced that it has expanded its partnership with Pharmacosmos A/S (Pharmacosmos), to include exclusive rights to ...
June 19, 2024 | News
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas. ...
June 17, 2024 | News
Most Read
Bio Jobs
News